Bergen, Norway, 11 April 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the appointment of Cristina Oliva, MD as
Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior
leadership team heading up clinical development of BerGenBio's selective AXL
inhibitor programs.

Cristina is a Board-certified oncologist and brings over 20 years of senior
clinical development experience across large pharmaceutical, biotechnology and
Clinical Research Organizations (CROs). Most recently Cristina was Vice
President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd,
where she led the development of decentralized trials and established and led
the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA,
Cristina held senior positions leading oncology development programs for Nordic
Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

Martin Olin, Chief Executive Officer of BerGenBio, commented: "I'm delighted to
welcome Cristina as our new Chief Medical Officer. Cristina's leadership
experience within oncology drug development across big pharma, biotech and CRO
environments will be instrumental in executing BerGenBio's development strategy
for our AXL inhibitor programs, including our most advanced program bemcentinib,
currently in phase II trials."

On her appointment as Chief Medical Officer at BerGenBio, Cristina Oliva, MD,
commented:"BerGenBio is on the frontier of developing novel, highly selective
AXL inhibitors for the treatment of severe diseases such as oncology and
respiratory infections. I'm very excited to join BerGenBio at this critical
phase and look forward to working with the senior leadership team to help
further advance its AXL inhibitor programs."


For BerGenBio: Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange